Salvage therapy with XXXX , @entity1260 , @entity619 , and @entity901 (GIDOX) for @entity1892 : a consortium for improving survival of lymphoma (CISL) trial.

@entity901 @entity1 @entity137 @entity882 @entity619 @entity1892 @entity1398 @entity1073 @entity1260 @entity1893 @entity136
BACKGROUND: We investigated response rates to and @entity137 of @entity136 , @entity1260 , @entity619 , and @entity901 (GIDOX) for the treatment of relapsed or refractory aggressive @entity1892 ( @entity1893 ). @entity1 AND METHODS: @entity1 with recurrent or refractory diffuse large @entity1892 or @entity1073 (DLBCL) were eligible for enrollment in this study. Treatment consisted of @entity136 1,000 mg/m(2) intravenously (i.v.) on Days 1 and 8, @entity1260 2,000 mg/m(2) i.v. on Day 1, @entity619 40 mg orally on Days 1-4, and @entity901 130 mg/m(2) i.v. on Day 2, every 21 days. The primary goal of treatment was to establish a response rate after three cycles. Afterwards, @entity1 could proceed to high-dose chemotherapy followed by autologous stem cell transplantation (HDC-ASCT) or receive up to six treatment cycles. RESULTS: Twenty-seven eligible @entity1 were evaluated for @entity137 and response. The median age of the @entity1 was 54 years (range, 18-75 years), and most had DLBCL. After three cycles, there were four CR (15%) and 10 PR (37%) for an overall response rate (RR) of 52%. Among a total of 88 GIDOX cycles, grade 3 and 4 @entity1398 occurred in 33% and 16% of the cycles, respectively. Likewise, grade 3 and 4 @entity882 occurred in 14% and 16% of the cycles, respectively. Two @entity1 (2%) experienced @entity1398 , while seven @entity1 (26%) proceeded to HDC-ASCT. CONCLUSIONS: GIDOX is an active salvage regimen for aggressive B-cell @entity1893 and can be tolerated by @entity1 with acceptable @entity137 .
